Sai Life Sciences, a Contract Research, Development, and Manufacturing Organization (CRDMO) focused on innovation, has announced the successful completion of Phase II of its new Production Block (PB-11) at the company’s primary API manufacturing
Eli Lilly and Company announced positive top-line results in the Phase 3 ATTAIN-2 trial that evaluated, orforglipron, an investigational oral GLP-1 receptor agonist in adults with obesity or overweight and type 2 diabetes. The ATTAIN-2 trial showed
The plan to combine these separately listed businesses under the Dr. Agarwal's Group has been accepted by the boards of directors of Dr. Agarwal's Health Care Limited (AHCL) and Dr. Agarwal's Eye Hospital Limited (AEHL).
Bristol Myers Squibb presented major clinical and real-world results of its cardiovascular line at the European Society of Cardiology (ESC) Congress, which took place between August 29 and September 1, 2025, in Madrid, Spain. New data on Camzyos (mav
The second chapter of Garmin India's strategic partnership with Apollo HealthAxis, a division of Apollo Hospitals, aims to enhance chronic illness management, health monitoring, and general wellbeing across India. The partnership has entered a new
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. market availability of the first generic version of Saxenda
MedGenome unveiled the first CNS Tumour Methylation Classifier Test in India, which is a futuristic diagnostic tool that can recognize and categorize
GSK has made known the delivery of its cutting-edge oncology treatment Jemperli (dostarlimab) and Zejula (niraparib) in India, a considerable move to elevate the provision of precision cancer treatments.
Bayer has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for gadoquatrane, an investigational macrocyclic gadolinium-based contrast agent
If not properly handled, shifting GST rates for medical equipment could affect domestic competitiveness, the Association of Indian medical Device Industry (AiMeD) said. The majority of devices are now subject to 12% GST, whilst inputs are subject to
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")